#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Rheumatoid arthritis ( RA ) is an autoimmune condition , characterized by symmetrical joint inflammation , that affects approximately 1 % of the world ’s population .
3-1	17-27	Rheumatoid	object|abstract[4]	new|new[4]	appos|appos	3-4[0_4]|3-4[0_4]
3-2	28-37	arthritis	abstract[4]	new[4]	_	_
3-3	38-39	(	_	_	_	_
3-4	40-42	RA	abstract	giv	coref	3-7[6_0]
3-5	43-44	)	_	_	_	_
3-6	45-47	is	_	_	_	_
3-7	48-50	an	abstract[6]	giv[6]	coref	4-1[0_6]
3-8	51-61	autoimmune	abstract[6]	giv[6]	_	_
3-9	62-71	condition	abstract[6]	giv[6]	_	_
3-10	72-73	,	_	_	_	_
3-11	74-87	characterized	_	_	_	_
3-12	88-90	by	_	_	_	_
3-13	91-102	symmetrical	abstract[7]	new[7]	_	_
3-14	103-108	joint	abstract[7]	new[7]	_	_
3-15	109-121	inflammation	abstract[7]	new[7]	_	_
3-16	122-123	,	_	_	_	_
3-17	124-128	that	_	_	_	_
3-18	129-136	affects	_	_	_	_
3-19	137-150	approximately	quantity[8]	new[8]	_	_
3-20	151-152	1	quantity[8]	new[8]	_	_
3-21	153-154	%	quantity[8]	new[8]	_	_
3-22	155-157	of	quantity[8]	new[8]	_	_
3-23	158-161	the	quantity[8]|abstract[10]	new[8]|new[10]	_	_
3-24	162-167	world	quantity[8]|place[9]|abstract[10]	new[8]|new[9]|new[10]	_	_
3-25	168-170	’s	quantity[8]|place[9]|abstract[10]	new[8]|new[9]|new[10]	_	_
3-26	171-181	population	quantity[8]|abstract[10]	new[8]|new[10]	_	_
3-27	182-183	.	_	_	_	_

#Text=RA is characterized mainly by synovium hyperplasia and a joint destruction process .
4-1	184-186	RA	abstract	giv	coref	5-24
4-2	187-189	is	_	_	_	_
4-3	190-203	characterized	_	_	_	_
4-4	204-210	mainly	_	_	_	_
4-5	211-213	by	_	_	_	_
4-6	214-222	synovium	place|abstract[13]	new|new[13]	_	_
4-7	223-234	hyperplasia	abstract[13]	new[13]	_	_
4-8	235-238	and	_	_	_	_
4-9	239-240	a	abstract[15]	new[15]	coref	8-34[53_15]
4-10	241-246	joint	abstract[15]	new[15]	_	_
4-11	247-258	destruction	event|abstract[15]	new|new[15]	coref	17-31
4-12	259-266	process	abstract[15]	new[15]	_	_
4-13	267-268	.	_	_	_	_

#Text=In this scenario , immune cells and the inflammatory microenvironment that they create in affected joints are key components in the pathophysiology of RA .
5-1	269-271	In	_	_	_	_
5-2	272-276	this	event[16]	new[16]	_	_
5-3	277-285	scenario	event[16]	new[16]	_	_
5-4	286-287	,	_	_	_	_
5-5	288-294	immune	object[17]|abstract[18]	new[17]|new[18]	ana|coref|ana|coref	5-12[0_18]|15-29[118_17]|5-12[0_18]|15-29[118_17]
5-6	295-300	cells	object[17]|abstract[18]	new[17]|new[18]	_	_
5-7	301-304	and	abstract[18]	new[18]	_	_
5-8	305-308	the	abstract[18]|abstract[19]	new[18]|new[19]	coref	5-18[22_19]
5-9	309-321	inflammatory	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-10	322-338	microenvironment	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-11	339-343	that	_	_	_	_
5-12	344-348	they	abstract	giv	_	_
5-13	349-355	create	_	_	_	_
5-14	356-358	in	_	_	_	_
5-15	359-367	affected	place[21]	new[21]	_	_
5-16	368-374	joints	place[21]	new[21]	_	_
5-17	375-378	are	_	_	_	_
5-18	379-382	key	abstract[22]	giv[22]	_	_
5-19	383-393	components	abstract[22]	giv[22]	_	_
5-20	394-396	in	abstract[22]	giv[22]	_	_
5-21	397-400	the	abstract[22]|abstract[23]	giv[22]|new[23]	ana	6-3[0_23]
5-22	401-416	pathophysiology	abstract[22]|abstract[23]	giv[22]|new[23]	_	_
5-23	417-419	of	abstract[22]|abstract[23]	giv[22]|new[23]	_	_
5-24	420-422	RA	abstract[22]|abstract[23]|abstract	giv[22]|new[23]|giv	coref	7-1
5-25	423-424	.	_	_	_	_

#Text=Moreover , it is well-described that during the inflammatory stages of the disease , extra-articular manifestations are common , which involve other tissues or organs .
6-1	425-433	Moreover	_	_	_	_
6-2	434-435	,	_	_	_	_
6-3	436-438	it	abstract	giv	_	_
6-4	439-441	is	_	_	_	_
6-5	442-456	well-described	_	_	_	_
6-6	457-461	that	_	_	_	_
6-7	462-468	during	_	_	_	_
6-8	469-472	the	abstract[26]	new[26]	_	_
6-9	473-485	inflammatory	abstract[26]	new[26]	_	_
6-10	486-492	stages	abstract[26]	new[26]	_	_
6-11	493-495	of	abstract[26]	new[26]	_	_
6-12	496-499	the	abstract[26]|abstract[27]	new[26]|new[27]	coref	8-22[0_27]
6-13	500-507	disease	abstract[26]|abstract[27]	new[26]|new[27]	_	_
6-14	508-509	,	_	_	_	_
6-15	510-525	extra-articular	abstract[28]	new[28]	_	_
6-16	526-540	manifestations	abstract[28]	new[28]	_	_
6-17	541-544	are	_	_	_	_
6-18	545-551	common	_	_	_	_
6-19	552-553	,	_	_	_	_
6-20	554-559	which	_	_	_	_
6-21	560-567	involve	_	_	_	_
6-22	568-573	other	object[29]	new[29]	coref	16-12[125_29]
6-23	574-581	tissues	object[29]	new[29]	_	_
6-24	582-584	or	_	_	_	_
6-25	585-591	organs	object	new	_	_
6-26	592-593	.	_	_	_	_

#Text=RA patients are at risk of systemic complications and several co-morbidities , including osteoporosis and frequent vertebral and hip fragility fractures .
7-1	594-596	RA	abstract|person[32]	giv|new[32]	coref|coref|coref|coref	8-8|8-8[43_32]|8-8|8-8[43_32]
7-2	597-605	patients	person[32]	new[32]	_	_
7-3	606-609	are	_	_	_	_
7-4	610-612	at	_	_	_	_
7-5	613-617	risk	abstract[33]	new[33]	coref	8-17[46_33]
7-6	618-620	of	abstract[33]	new[33]	_	_
7-7	621-629	systemic	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-8	630-643	complications	abstract[33]|abstract[34]	new[33]|new[34]	_	_
7-9	644-647	and	abstract[33]	new[33]	_	_
7-10	648-655	several	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-11	656-670	co-morbidities	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-12	671-672	,	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-13	673-682	including	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-14	683-695	osteoporosis	abstract[33]|abstract[35]|abstract	new[33]|new[35]|new	_	_
7-15	696-699	and	abstract[33]|abstract[35]	new[33]|new[35]	_	_
7-16	700-708	frequent	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	coref	8-5[41_38]
7-17	709-718	vertebral	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-18	719-722	and	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-19	723-726	hip	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-20	727-736	fragility	abstract[33]|abstract[35]|abstract|event[38]	new[33]|new[35]|new|new[38]	_	_
7-21	737-746	fractures	abstract[33]|abstract[35]|event[38]	new[33]|new[35]|new[38]	_	_
7-22	747-748	.	_	_	_	_

#Text=The incidence rate of overall fractures in RA patients is 33 per 1000 person-years , and the risk is increased with disease activity and associated with overexpression of pro-inflammatory cytokines that can disturb the bone remodeling process .
8-1	749-752	The	abstract[40]	new[40]	_	_
8-2	753-762	incidence	abstract|abstract[40]	new|new[40]	_	_
8-3	763-767	rate	abstract[40]	new[40]	_	_
8-4	768-770	of	abstract[40]	new[40]	_	_
8-5	771-778	overall	abstract[40]|event[41]	new[40]|giv[41]	_	_
8-6	779-788	fractures	abstract[40]|event[41]	new[40]|giv[41]	_	_
8-7	789-791	in	abstract[40]|event[41]	new[40]|giv[41]	_	_
8-8	792-794	RA	abstract[40]|event[41]|abstract|person[43]	new[40]|giv[41]|giv|giv[43]	coref|coref	9-24|9-24
8-9	795-803	patients	abstract[40]|event[41]|person[43]	new[40]|giv[41]|giv[43]	_	_
8-10	804-806	is	_	_	_	_
8-11	807-809	33	quantity[44]	new[44]	_	_
8-12	810-813	per	quantity[44]	new[44]	_	_
8-13	814-818	1000	quantity[44]|quantity[45]	new[44]|new[45]	_	_
8-14	819-831	person-years	quantity[44]|quantity[45]	new[44]|new[45]	_	_
8-15	832-833	,	_	_	_	_
8-16	834-837	and	_	_	_	_
8-17	838-841	the	abstract[46]	giv[46]	_	_
8-18	842-846	risk	abstract[46]	giv[46]	_	_
8-19	847-849	is	_	_	_	_
8-20	850-859	increased	_	_	_	_
8-21	860-864	with	_	_	_	_
8-22	865-872	disease	abstract|abstract[48]	giv|new[48]	coref|coref|coref|coref	12-11|22-12[197_48]|12-11|22-12[197_48]
8-23	873-881	activity	abstract[48]	new[48]	_	_
8-24	882-885	and	_	_	_	_
8-25	886-896	associated	_	_	_	_
8-26	897-901	with	_	_	_	_
8-27	902-916	overexpression	abstract[49]	new[49]	_	_
8-28	917-919	of	abstract[49]	new[49]	_	_
8-29	920-936	pro-inflammatory	abstract[49]|abstract[50]	new[49]|new[50]	coref	12-25[86_50]
8-30	937-946	cytokines	abstract[49]|abstract[50]	new[49]|new[50]	_	_
8-31	947-951	that	_	_	_	_
8-32	952-955	can	_	_	_	_
8-33	956-963	disturb	_	_	_	_
8-34	964-967	the	abstract[53]	giv[53]	coref	9-20[60_53]
8-35	968-972	bone	object|abstract[53]	new|giv[53]	_	_
8-36	973-983	remodeling	event|abstract[53]	new|giv[53]	_	_
8-37	984-991	process	abstract[53]	giv[53]	_	_
8-38	992-993	.	_	_	_	_

#Text=Over the last decades , animal models — especially the rodent models — have been crucial tools for understanding the biologic process of RA , and their use can aid in developing new therapeutic strategies for fracture healing in RA inflammatory conditions .
9-1	994-998	Over	_	_	_	_
9-2	999-1002	the	time[54]	new[54]	_	_
9-3	1003-1007	last	time[54]	new[54]	_	_
9-4	1008-1015	decades	time[54]	new[54]	_	_
9-5	1016-1017	,	_	_	_	_
9-6	1018-1024	animal	person|abstract[56]	new|new[56]	appos|coref|appos|coref	9-9[58_56]|10-6|9-9[58_56]|10-6
9-7	1025-1031	models	abstract[56]	new[56]	_	_
9-8	1032-1033	—	_	_	_	_
9-9	1034-1044	especially	abstract[58]	giv[58]	coref	9-16[59_58]
9-10	1045-1048	the	abstract[58]	giv[58]	_	_
9-11	1049-1055	rodent	animal|abstract[58]	new|giv[58]	_	_
9-12	1056-1062	models	abstract[58]	giv[58]	_	_
9-13	1063-1064	—	_	_	_	_
9-14	1065-1069	have	_	_	_	_
9-15	1070-1074	been	_	_	_	_
9-16	1075-1082	crucial	abstract[59]	giv[59]	ana	9-27[0_59]
9-17	1083-1088	tools	abstract[59]	giv[59]	_	_
9-18	1089-1092	for	_	_	_	_
9-19	1093-1106	understanding	_	_	_	_
9-20	1107-1110	the	abstract[60]	giv[60]	coref	12-43[93_60]
9-21	1111-1119	biologic	abstract[60]	giv[60]	_	_
9-22	1120-1127	process	abstract[60]	giv[60]	_	_
9-23	1128-1130	of	abstract[60]	giv[60]	_	_
9-24	1131-1133	RA	abstract[60]|abstract	giv[60]|giv	coref	9-40
9-25	1134-1135	,	_	_	_	_
9-26	1136-1139	and	_	_	_	_
9-27	1140-1145	their	abstract|abstract[63]	giv|new[63]	coref|coref|coref|coref	10-1[71_0]|18-6[146_63]|10-1[71_0]|18-6[146_63]
9-28	1146-1149	use	abstract[63]	new[63]	_	_
9-29	1150-1153	can	_	_	_	_
9-30	1154-1157	aid	_	_	_	_
9-31	1158-1160	in	_	_	_	_
9-32	1161-1171	developing	_	_	_	_
9-33	1172-1175	new	abstract[64]	new[64]	coref	12-49[94_64]
9-34	1176-1187	therapeutic	abstract[64]	new[64]	_	_
9-35	1188-1198	strategies	abstract[64]	new[64]	_	_
9-36	1199-1202	for	_	_	_	_
9-37	1203-1211	fracture	abstract	new	_	_
9-38	1212-1219	healing	_	_	_	_
9-39	1220-1222	in	_	_	_	_
9-40	1223-1225	RA	abstract|abstract[67]	giv|new[67]	coref|coref|coref|coref	10-18|18-29[155_67]|10-18|18-29[155_67]
9-41	1226-1238	inflammatory	abstract[67]	new[67]	_	_
9-42	1239-1249	conditions	abstract[67]	new[67]	_	_
9-43	1250-1251	.	_	_	_	_

#Text=Collagen induced-arthritis ( CIA ) animal models have been one of the most widely used models in RA research .
10-1	1252-1260	Collagen	organization|abstract[71]	new|giv[71]	coref|coref	10-12[73_71]|10-12[73_71]
10-2	1261-1278	induced-arthritis	abstract[71]	giv[71]	_	_
10-3	1279-1280	(	abstract[71]	giv[71]	_	_
10-4	1281-1284	CIA	abstract|abstract[71]	new|giv[71]	coref	11-6
10-5	1285-1286	)	abstract[71]	giv[71]	_	_
10-6	1287-1293	animal	person|abstract[71]	giv|giv[71]	coref	11-10
10-7	1294-1300	models	abstract[71]	giv[71]	_	_
10-8	1301-1305	have	_	_	_	_
10-9	1306-1310	been	_	_	_	_
10-10	1311-1314	one	abstract[72]	new[72]	_	_
10-11	1315-1317	of	abstract[72]	new[72]	_	_
10-12	1318-1321	the	abstract[72]|abstract[73]	new[72]|giv[73]	coref	21-9[175_73]
10-13	1322-1326	most	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-14	1327-1333	widely	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-15	1334-1338	used	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-16	1339-1345	models	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-17	1346-1348	in	abstract[72]|abstract[73]	new[72]|giv[73]	_	_
10-18	1349-1351	RA	abstract[72]|abstract[73]|abstract|abstract[75]	new[72]|giv[73]|giv|new[75]	coref|coref	11-14|11-14
10-19	1352-1360	research	abstract[72]|abstract[73]|abstract[75]	new[72]|giv[73]|new[75]	_	_
10-20	1361-1362	.	_	_	_	_

#Text=Originally described by Trentham , CIA is a reproducible animal experimental model of RA .
11-1	1363-1373	Originally	_	_	_	_
11-2	1374-1383	described	_	_	_	_
11-3	1384-1386	by	_	_	_	_
11-4	1387-1395	Trentham	person	new	_	_
11-5	1396-1397	,	_	_	_	_
11-6	1398-1401	CIA	abstract	giv	coref	11-8[79_0]
11-7	1402-1404	is	_	_	_	_
11-8	1405-1406	a	abstract[79]	giv[79]	coref	12-38[92_79]
11-9	1407-1419	reproducible	abstract[79]	giv[79]	_	_
11-10	1420-1426	animal	person|abstract[79]	giv|giv[79]	_	_
11-11	1427-1439	experimental	abstract[79]	giv[79]	_	_
11-12	1440-1445	model	abstract[79]	giv[79]	_	_
11-13	1446-1448	of	abstract[79]	giv[79]	_	_
11-14	1449-1451	RA	abstract[79]|abstract	giv[79]|giv	coref	12-7[82_0]
11-15	1452-1453	.	_	_	_	_

#Text=In fact , the similarity to human RA regarding the disease clinical , histological , and immunological signals — including high articular levels of inflammatory cytokines — like tumor necrosis factor-α ( TNF-α ) , make it an invaluable model to study the pathologic process and to search new therapeutic strategies .
12-1	1454-1456	In	_	_	_	_
12-2	1457-1461	fact	_	_	_	_
12-3	1462-1463	,	_	_	_	_
12-4	1464-1467	the	abstract[81]	new[81]	_	_
12-5	1468-1478	similarity	abstract[81]	new[81]	_	_
12-6	1479-1481	to	abstract[81]	new[81]	_	_
12-7	1482-1487	human	abstract[81]|abstract[82]	new[81]|giv[82]	coref	15-4[0_82]
12-8	1488-1490	RA	abstract[81]|abstract[82]	new[81]|giv[82]	_	_
12-9	1491-1500	regarding	_	_	_	_
12-10	1501-1504	the	abstract[84]	new[84]	_	_
12-11	1505-1512	disease	abstract|abstract[84]	giv|new[84]	_	_
12-12	1513-1521	clinical	abstract[84]	new[84]	_	_
12-13	1522-1523	,	abstract[84]	new[84]	_	_
12-14	1524-1536	histological	abstract[84]	new[84]	_	_
12-15	1537-1538	,	abstract[84]	new[84]	_	_
12-16	1539-1542	and	abstract[84]	new[84]	_	_
12-17	1543-1556	immunological	abstract[84]	new[84]	_	_
12-18	1557-1564	signals	abstract[84]	new[84]	_	_
12-19	1565-1566	—	abstract[84]	new[84]	_	_
12-20	1567-1576	including	abstract[84]	new[84]	_	_
12-21	1577-1581	high	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-22	1582-1591	articular	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-23	1592-1598	levels	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-24	1599-1601	of	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-25	1602-1614	inflammatory	abstract[84]|abstract[85]|abstract[86]	new[84]|new[85]|giv[86]	_	_
12-26	1615-1624	cytokines	abstract[84]|abstract[85]|abstract[86]	new[84]|new[85]|giv[86]	_	_
12-27	1625-1626	—	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-28	1627-1631	like	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-29	1632-1637	tumor	abstract[84]|abstract[85]|abstract|abstract[89]	new[84]|new[85]|new|new[89]	appos|appos	12-33[0_89]|12-33[0_89]
12-30	1638-1646	necrosis	abstract[84]|abstract[85]|abstract|abstract[89]	new[84]|new[85]|new|new[89]	_	_
12-31	1647-1655	factor-α	abstract[84]|abstract[85]|abstract[89]	new[84]|new[85]|new[89]	_	_
12-32	1656-1657	(	_	_	_	_
12-33	1658-1663	TNF-α	abstract	giv	ana	12-37
12-34	1664-1665	)	_	_	_	_
12-35	1666-1667	,	_	_	_	_
12-36	1668-1672	make	_	_	_	_
12-37	1673-1675	it	abstract	giv	coref	13-22
12-38	1676-1678	an	abstract[92]	giv[92]	coref	13-4[97_92]
12-39	1679-1689	invaluable	abstract[92]	giv[92]	_	_
12-40	1690-1695	model	abstract[92]	giv[92]	_	_
12-41	1696-1698	to	_	_	_	_
12-42	1699-1704	study	_	_	_	_
12-43	1705-1708	the	abstract[93]	giv[93]	_	_
12-44	1709-1719	pathologic	abstract[93]	giv[93]	_	_
12-45	1720-1727	process	abstract[93]	giv[93]	_	_
12-46	1728-1731	and	_	_	_	_
12-47	1732-1734	to	_	_	_	_
12-48	1735-1741	search	_	_	_	_
12-49	1742-1745	new	abstract[94]	giv[94]	_	_
12-50	1746-1757	therapeutic	abstract[94]	giv[94]	_	_
12-51	1758-1768	strategies	abstract[94]	giv[94]	_	_
12-52	1769-1770	.	_	_	_	_

#Text=The response to rat CIA has been reported to involve macrophages , T and B lymphocytes , and mediators such as TNF-α , Interleukin ( IL)-1β , IL-6 , and IL-17 .
13-1	1771-1774	The	abstract[95]	new[95]	coref	14-3[108_95]
13-2	1775-1783	response	abstract[95]	new[95]	_	_
13-3	1784-1786	to	abstract[95]	new[95]	_	_
13-4	1787-1790	rat	abstract[95]|animal|abstract[97]	new[95]|new|giv[97]	coref|coref	14-7[109_97]|14-7[109_97]
13-5	1791-1794	CIA	abstract[95]|abstract[97]	new[95]|giv[97]	_	_
13-6	1795-1798	has	_	_	_	_
13-7	1799-1803	been	_	_	_	_
13-8	1804-1812	reported	_	_	_	_
13-9	1813-1815	to	_	_	_	_
13-10	1816-1823	involve	_	_	_	_
13-11	1824-1835	macrophages	animal	new	_	_
13-12	1836-1837	,	_	_	_	_
13-13	1838-1839	T	person	new	_	_
13-14	1840-1843	and	_	_	_	_
13-15	1844-1845	B	place|person[101]	new|new[101]	_	_
13-16	1846-1857	lymphocytes	person[101]	new[101]	_	_
13-17	1858-1859	,	_	_	_	_
13-18	1860-1863	and	_	_	_	_
13-19	1864-1873	mediators	person[102]	new[102]	_	_
13-20	1874-1878	such	person[102]	new[102]	_	_
13-21	1879-1881	as	person[102]	new[102]	_	_
13-22	1882-1887	TNF-α	person[102]|abstract	new[102]|giv	_	_
13-23	1888-1889	,	_	_	_	_
13-24	1890-1901	Interleukin	object	new	_	_
13-25	1902-1903	(	_	_	_	_
13-26	1904-1910	IL)-1β	abstract	new	_	_
13-27	1911-1912	,	_	_	_	_
13-28	1913-1917	IL-6	abstract	new	coref	21-53[191_0]
13-29	1918-1919	,	_	_	_	_
13-30	1920-1923	and	_	_	_	_
13-31	1924-1929	IL-17	abstract	new	_	_
13-32	1930-1931	.	_	_	_	_

#Text=Nonetheless , the systemic response in this model has not been well characterized so far .
14-1	1932-1943	Nonetheless	_	_	_	_
14-2	1944-1945	,	_	_	_	_
14-3	1946-1949	the	abstract[108]	giv[108]	_	_
14-4	1950-1958	systemic	abstract[108]	giv[108]	_	_
14-5	1959-1967	response	abstract[108]	giv[108]	_	_
14-6	1968-1970	in	abstract[108]	giv[108]	_	_
14-7	1971-1975	this	abstract[108]|abstract[109]	giv[108]|giv[109]	coref	17-15[0_109]
14-8	1976-1981	model	abstract[108]|abstract[109]	giv[108]|giv[109]	_	_
14-9	1982-1985	has	_	_	_	_
14-10	1986-1989	not	_	_	_	_
14-11	1990-1994	been	_	_	_	_
14-12	1995-1999	well	_	_	_	_
14-13	2000-2013	characterized	_	_	_	_
14-14	2014-2016	so	_	_	_	_
14-15	2017-2020	far	_	_	_	_
14-16	2021-2022	.	_	_	_	_

#Text=Importantly , current RA treatments do not promote joint repair , and several efforts are being made to develop new therapies , especially based in cell approaches using mesenchymal stem/stromal cells ( MSC ) .
15-1	2023-2034	Importantly	_	_	_	_
15-2	2035-2036	,	_	_	_	_
15-3	2037-2044	current	abstract[111]	new[111]	_	_
15-4	2045-2047	RA	abstract|abstract[111]	giv|new[111]	coref	17-12
15-5	2048-2058	treatments	abstract[111]	new[111]	_	_
15-6	2059-2061	do	_	_	_	_
15-7	2062-2065	not	_	_	_	_
15-8	2066-2073	promote	_	_	_	_
15-9	2074-2079	joint	abstract[112]	new[112]	coref	16-43[134_112]
15-10	2080-2086	repair	abstract[112]	new[112]	_	_
15-11	2087-2088	,	_	_	_	_
15-12	2089-2092	and	_	_	_	_
15-13	2093-2100	several	abstract[113]	new[113]	_	_
15-14	2101-2108	efforts	abstract[113]	new[113]	_	_
15-15	2109-2112	are	_	_	_	_
15-16	2113-2118	being	_	_	_	_
15-17	2119-2123	made	_	_	_	_
15-18	2124-2126	to	_	_	_	_
15-19	2127-2134	develop	_	_	_	_
15-20	2135-2138	new	abstract[114]	new[114]	_	_
15-21	2139-2148	therapies	abstract[114]	new[114]	_	_
15-22	2149-2150	,	_	_	_	_
15-23	2151-2161	especially	_	_	_	_
15-24	2162-2167	based	_	_	_	_
15-25	2168-2170	in	_	_	_	_
15-26	2171-2175	cell	place|abstract[116]	new|new[116]	coref|coref	16-39|16-39
15-27	2176-2186	approaches	abstract[116]	new[116]	_	_
15-28	2187-2192	using	_	_	_	_
15-29	2193-2204	mesenchymal	animal|object[118]	new|giv[118]	appos|coref|appos|coref	15-33[0_118]|16-12|15-33[0_118]|16-12
15-30	2205-2217	stem/stromal	object[118]	giv[118]	_	_
15-31	2218-2223	cells	object[118]	giv[118]	_	_
15-32	2224-2225	(	_	_	_	_
15-33	2226-2229	MSC	object	giv	coref	16-1
15-34	2230-2231	)	_	_	_	_
15-35	2232-2233	.	_	_	_	_

#Text=MSC are multipotent progenitor cells with the potential to differentiate into mesenchymal lineage tissues ( e. g. , bone , cartilage , and adipose tissue ) , described to have immunomodulatory roles , being capable of recruiting different cell types and promoting tissue repair .
16-1	2234-2237	MSC	object	giv	coref	16-3[121_0]
16-2	2238-2241	are	_	_	_	_
16-3	2242-2253	multipotent	object[121]	giv[121]	coref	17-4[0_121]
16-4	2254-2264	progenitor	object[121]	giv[121]	_	_
16-5	2265-2270	cells	object[121]	giv[121]	_	_
16-6	2271-2275	with	object[121]	giv[121]	_	_
16-7	2276-2279	the	object[121]|abstract[122]	giv[121]|new[122]	_	_
16-8	2280-2289	potential	object[121]|abstract[122]	giv[121]|new[122]	_	_
16-9	2290-2292	to	_	_	_	_
16-10	2293-2306	differentiate	_	_	_	_
16-11	2307-2311	into	_	_	_	_
16-12	2312-2323	mesenchymal	abstract|object[125]	giv|giv[125]	appos|appos	16-19[0_125]|16-19[0_125]
16-13	2324-2331	lineage	abstract|object[125]	new|giv[125]	_	_
16-14	2332-2339	tissues	object[125]	giv[125]	_	_
16-15	2340-2341	(	_	_	_	_
16-16	2342-2344	e.	_	_	_	_
16-17	2345-2347	g.	_	_	_	_
16-18	2348-2349	,	_	_	_	_
16-19	2350-2354	bone	object	giv	appos	16-21
16-20	2355-2356	,	_	_	_	_
16-21	2357-2366	cartilage	object	giv	appos	16-24[129_0]
16-22	2367-2368	,	_	_	_	_
16-23	2369-2372	and	_	_	_	_
16-24	2373-2380	adipose	abstract|object[129]	new|giv[129]	coref|coref	20-12[0_129]|20-12[0_129]
16-25	2381-2387	tissue	object[129]	giv[129]	_	_
16-26	2388-2389	)	_	_	_	_
16-27	2390-2391	,	_	_	_	_
16-28	2392-2401	described	_	_	_	_
16-29	2402-2404	to	_	_	_	_
16-30	2405-2409	have	_	_	_	_
16-31	2410-2426	immunomodulatory	abstract[130]	new[130]	_	_
16-32	2427-2432	roles	abstract[130]	new[130]	_	_
16-33	2433-2434	,	_	_	_	_
16-34	2435-2440	being	_	_	_	_
16-35	2441-2448	capable	_	_	_	_
16-36	2449-2451	of	_	_	_	_
16-37	2452-2462	recruiting	_	_	_	_
16-38	2463-2472	different	abstract[132]	new[132]	_	_
16-39	2473-2477	cell	object|abstract[132]	giv|new[132]	_	_
16-40	2478-2483	types	abstract[132]	new[132]	_	_
16-41	2484-2487	and	_	_	_	_
16-42	2488-2497	promoting	_	_	_	_
16-43	2498-2504	tissue	object|abstract[134]	new|giv[134]	_	_
16-44	2505-2511	repair	abstract[134]	giv[134]	_	_
16-45	2512-2513	.	_	_	_	_

#Text=The transplantation of MSC has been reported to ameliorate or delay RA onset in CIA animals , partially mediated by inflammatory signaling suppression , and thereby reducing joint swelling and destruction .
17-1	2514-2517	The	event[135]	new[135]	coref	18-9[148_135]
17-2	2518-2533	transplantation	event[135]	new[135]	_	_
17-3	2534-2536	of	event[135]	new[135]	_	_
17-4	2537-2540	MSC	event[135]|object	new[135]|giv	coref	18-9
17-5	2541-2544	has	_	_	_	_
17-6	2545-2549	been	_	_	_	_
17-7	2550-2558	reported	_	_	_	_
17-8	2559-2561	to	_	_	_	_
17-9	2562-2572	ameliorate	_	_	_	_
17-10	2573-2575	or	_	_	_	_
17-11	2576-2581	delay	_	_	_	_
17-12	2582-2584	RA	abstract|abstract[138]	giv|new[138]	coref|coref	19-6[157_0]|19-6[157_0]
17-13	2585-2590	onset	abstract[138]	new[138]	_	_
17-14	2591-2593	in	abstract[138]	new[138]	_	_
17-15	2594-2597	CIA	abstract[138]|organization|animal[140]	new[138]|giv|new[140]	coref|coref|coref|coref	18-16|18-16[150_140]|18-16|18-16[150_140]
17-16	2598-2605	animals	abstract[138]|animal[140]	new[138]|new[140]	_	_
17-17	2606-2607	,	_	_	_	_
17-18	2608-2617	partially	_	_	_	_
17-19	2618-2626	mediated	_	_	_	_
17-20	2627-2629	by	_	_	_	_
17-21	2630-2642	inflammatory	abstract[142]	new[142]	_	_
17-22	2643-2652	signaling	abstract|abstract[142]	new|new[142]	_	_
17-23	2653-2664	suppression	abstract[142]	new[142]	_	_
17-24	2665-2666	,	_	_	_	_
17-25	2667-2670	and	_	_	_	_
17-26	2671-2678	thereby	_	_	_	_
17-27	2679-2687	reducing	_	_	_	_
17-28	2688-2693	joint	abstract[143]	new[143]	_	_
17-29	2694-2702	swelling	abstract[143]	new[143]	_	_
17-30	2703-2706	and	_	_	_	_
17-31	2707-2718	destruction	event	giv	_	_
17-32	2719-2720	.	_	_	_	_

#Text=Although the available evidence supports the use of MSC transplantation as a cell-based strategy in CIA animals , data on the biology of endogenous CIA animals-derived MSC in basal conditions is scarce .
18-1	2721-2729	Although	_	_	_	_
18-2	2730-2733	the	abstract[145]	new[145]	_	_
18-3	2734-2743	available	abstract[145]	new[145]	_	_
18-4	2744-2752	evidence	abstract[145]	new[145]	_	_
18-5	2753-2761	supports	_	_	_	_
18-6	2762-2765	the	abstract[146]	giv[146]	_	_
18-7	2766-2769	use	abstract[146]	giv[146]	_	_
18-8	2770-2772	of	abstract[146]	giv[146]	_	_
18-9	2773-2776	MSC	abstract[146]|object|event[148]	giv[146]|giv|giv[148]	coref|coref	18-24[154_0]|18-24[154_0]
18-10	2777-2792	transplantation	abstract[146]|event[148]	giv[146]|giv[148]	_	_
18-11	2793-2795	as	_	_	_	_
18-12	2796-2797	a	_	_	_	_
18-13	2798-2808	cell-based	_	_	_	_
18-14	2809-2817	strategy	_	_	_	_
18-15	2818-2820	in	_	_	_	_
18-16	2821-2824	CIA	organization|animal[150]	giv|giv[150]	coref|coref|coref|coref	18-25|21-16[177_150]|18-25|21-16[177_150]
18-17	2825-2832	animals	animal[150]	giv[150]	_	_
18-18	2833-2834	,	_	_	_	_
18-19	2835-2839	data	abstract[151]	new[151]	_	_
18-20	2840-2842	on	abstract[151]	new[151]	_	_
18-21	2843-2846	the	abstract[151]|abstract[152]	new[151]|new[152]	_	_
18-22	2847-2854	biology	abstract[151]|abstract[152]	new[151]|new[152]	_	_
18-23	2855-2857	of	abstract[151]|abstract[152]	new[151]|new[152]	_	_
18-24	2858-2868	endogenous	abstract[151]|abstract[152]|object[154]	new[151]|new[152]|giv[154]	coref	19-14[159_154]
18-25	2869-2872	CIA	abstract[151]|abstract[152]|organization|object[154]	new[151]|new[152]|giv|giv[154]	coref	20-5
18-26	2873-2888	animals-derived	abstract[151]|abstract[152]|object[154]	new[151]|new[152]|giv[154]	_	_
18-27	2889-2892	MSC	abstract[151]|abstract[152]|object[154]	new[151]|new[152]|giv[154]	_	_
18-28	2893-2895	in	abstract[151]|abstract[152]|object[154]	new[151]|new[152]|giv[154]	_	_
18-29	2896-2901	basal	abstract[151]|abstract[152]|object[154]|abstract[155]	new[151]|new[152]|giv[154]|giv[155]	coref	20-15[164_155]
18-30	2902-2912	conditions	abstract[151]|abstract[152]|object[154]|abstract[155]	new[151]|new[152]|giv[154]|giv[155]	_	_
18-31	2913-2915	is	_	_	_	_
18-32	2916-2922	scarce	_	_	_	_
18-33	2923-2924	.	_	_	_	_

#Text=Moreover , the impact of the systemic inflammatory condition on biological properties of endogenous MSC has not been explored yet .
19-1	2925-2933	Moreover	_	_	_	_
19-2	2934-2935	,	_	_	_	_
19-3	2936-2939	the	abstract[156]	new[156]	_	_
19-4	2940-2946	impact	abstract[156]	new[156]	_	_
19-5	2947-2949	of	abstract[156]	new[156]	_	_
19-6	2950-2953	the	abstract[156]|abstract[157]	new[156]|giv[157]	coref	20-25[0_157]
19-7	2954-2962	systemic	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-8	2963-2975	inflammatory	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-9	2976-2985	condition	abstract[156]|abstract[157]	new[156]|giv[157]	_	_
19-10	2986-2988	on	abstract[156]	new[156]	_	_
19-11	2989-2999	biological	abstract[156]|abstract[158]	new[156]|new[158]	_	_
19-12	3000-3010	properties	abstract[156]|abstract[158]	new[156]|new[158]	_	_
19-13	3011-3013	of	abstract[156]|abstract[158]	new[156]|new[158]	_	_
19-14	3014-3024	endogenous	abstract[156]|abstract[158]|object[159]	new[156]|new[158]|giv[159]	coref	20-32[170_159]
19-15	3025-3028	MSC	abstract[156]|abstract[158]|object[159]	new[156]|new[158]|giv[159]	_	_
19-16	3029-3032	has	_	_	_	_
19-17	3033-3036	not	_	_	_	_
19-18	3037-3041	been	_	_	_	_
19-19	3042-3050	explored	_	_	_	_
19-20	3051-3054	yet	_	_	_	_
19-21	3055-3056	.	_	_	_	_

#Text=Herein , we propose CIA as a reliable model to study bone regeneration in inflammatory conditions , and additionally we investigate the effect of RA induction on the biological behavior of endogenous MSC as crucial cells involved in repair/regeneration .
20-1	3057-3063	Herein	_	_	_	_
20-2	3064-3065	,	_	_	_	_
20-3	3066-3068	we	person	acc	ana	20-20
20-4	3069-3076	propose	_	_	_	_
20-5	3077-3080	CIA	abstract	giv	coref	21-16
20-6	3081-3083	as	_	_	_	_
20-7	3084-3085	a	_	_	_	_
20-8	3086-3094	reliable	_	_	_	_
20-9	3095-3100	model	_	_	_	_
20-10	3101-3103	to	_	_	_	_
20-11	3104-3109	study	_	_	_	_
20-12	3110-3114	bone	object|abstract[163]	giv|new[163]	coref|coref	21-21|21-21
20-13	3115-3127	regeneration	abstract[163]	new[163]	_	_
20-14	3128-3130	in	_	_	_	_
20-15	3131-3143	inflammatory	abstract[164]	giv[164]	coref	22-57[214_164]
20-16	3144-3154	conditions	abstract[164]	giv[164]	_	_
20-17	3155-3156	,	_	_	_	_
20-18	3157-3160	and	_	_	_	_
20-19	3161-3173	additionally	_	_	_	_
20-20	3174-3176	we	person	giv	ana	21-1
20-21	3177-3188	investigate	_	_	_	_
20-22	3189-3192	the	abstract[166]	new[166]	_	_
20-23	3193-3199	effect	abstract[166]	new[166]	_	_
20-24	3200-3202	of	abstract[166]	new[166]	_	_
20-25	3203-3205	RA	abstract[166]|organization|abstract[168]	new[166]|giv|new[168]	coref|coref|coref|coref	22-8|22-7[195_168]|22-8|22-7[195_168]
20-26	3206-3215	induction	abstract[166]|abstract[168]	new[166]|new[168]	_	_
20-27	3216-3218	on	abstract[166]|abstract[168]	new[166]|new[168]	_	_
20-28	3219-3222	the	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-29	3223-3233	biological	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-30	3234-3242	behavior	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-31	3243-3245	of	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-32	3246-3256	endogenous	abstract[166]|abstract[168]|abstract[169]|object[170]	new[166]|new[168]|new[169]|giv[170]	coref	21-30[0_170]
20-33	3257-3260	MSC	abstract[166]|abstract[168]|abstract[169]|object[170]	new[166]|new[168]|new[169]|giv[170]	_	_
20-34	3261-3263	as	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-35	3264-3271	crucial	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-36	3272-3277	cells	abstract[166]|abstract[168]|abstract[169]	new[166]|new[168]|new[169]	_	_
20-37	3278-3286	involved	_	_	_	_
20-38	3287-3289	in	_	_	_	_
20-39	3290-3309	repair/regeneration	event	new	_	_
20-40	3310-3311	.	_	_	_	_

#Text=Our results have shown that the combination of the two models is feasible and that CIA animals respond to the bone injury with a significant increase of systemic myeloid cells number and their co-stimulatory molecules ( CD40 and CD86 ) expression , accompanied by increased levels of IL-13 , IL-2 , and IL-6 in plasma .
21-1	3312-3315	Our	person|abstract[173]	giv|new[173]	_	_
21-2	3316-3323	results	abstract[173]	new[173]	_	_
21-3	3324-3328	have	_	_	_	_
21-4	3329-3334	shown	_	_	_	_
21-5	3335-3339	that	_	_	_	_
21-6	3340-3343	the	abstract[174]	new[174]	_	_
21-7	3344-3355	combination	abstract[174]	new[174]	_	_
21-8	3356-3358	of	abstract[174]	new[174]	_	_
21-9	3359-3362	the	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-10	3363-3366	two	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-11	3367-3373	models	abstract[174]|abstract[175]	new[174]|giv[175]	_	_
21-12	3374-3376	is	_	_	_	_
21-13	3377-3385	feasible	_	_	_	_
21-14	3386-3389	and	_	_	_	_
21-15	3390-3394	that	_	_	_	_
21-16	3395-3398	CIA	organization|animal[177]	giv|giv[177]	ana|ana	21-33[0_177]|21-33[0_177]
21-17	3399-3406	animals	animal[177]	giv[177]	_	_
21-18	3407-3414	respond	_	_	_	_
21-19	3415-3417	to	_	_	_	_
21-20	3418-3421	the	event[179]	new[179]	_	_
21-21	3422-3426	bone	object|event[179]	giv|new[179]	_	_
21-22	3427-3433	injury	event[179]	new[179]	_	_
21-23	3434-3438	with	_	_	_	_
21-24	3439-3440	a	abstract[180]	new[180]	_	_
21-25	3441-3452	significant	abstract[180]	new[180]	_	_
21-26	3453-3461	increase	abstract[180]	new[180]	_	_
21-27	3462-3464	of	abstract[180]	new[180]	_	_
21-28	3465-3473	systemic	abstract[180]|abstract[183]	new[180]|new[183]	_	_
21-29	3474-3481	myeloid	abstract[180]|object|abstract[183]	new[180]|new|new[183]	_	_
21-30	3482-3487	cells	abstract[180]|object|abstract[183]	new[180]|giv|new[183]	coref	22-18[200_0]
21-31	3488-3494	number	abstract[180]|abstract[183]	new[180]|new[183]	_	_
21-32	3495-3498	and	abstract[180]	new[180]	_	_
21-33	3499-3504	their	abstract[180]|animal|abstract[185]	new[180]|giv|new[185]	appos|appos	21-37[186_185]|21-37[186_185]
21-34	3505-3519	co-stimulatory	abstract[180]|abstract[185]	new[180]|new[185]	_	_
21-35	3520-3529	molecules	abstract[180]|abstract[185]	new[180]|new[185]	_	_
21-36	3530-3531	(	_	_	_	_
21-37	3532-3536	CD40	abstract[186]	giv[186]	_	_
21-38	3537-3540	and	abstract[186]	giv[186]	_	_
21-39	3541-3545	CD86	abstract[186]	giv[186]	_	_
21-40	3546-3547	)	_	_	_	_
21-41	3548-3558	expression	abstract	new	coref	22-27[203_0]
21-42	3559-3560	,	_	_	_	_
21-43	3561-3572	accompanied	_	_	_	_
21-44	3573-3575	by	_	_	_	_
21-45	3576-3585	increased	abstract[188]	new[188]	_	_
21-46	3586-3592	levels	abstract[188]	new[188]	_	_
21-47	3593-3595	of	abstract[188]	new[188]	_	_
21-48	3596-3601	IL-13	abstract[188]|abstract	new[188]|new	_	_
21-49	3602-3603	,	abstract[188]	new[188]	_	_
21-50	3604-3608	IL-2	abstract[188]|abstract	new[188]|new	_	_
21-51	3609-3610	,	abstract[188]	new[188]	_	_
21-52	3611-3614	and	abstract[188]	new[188]	_	_
21-53	3615-3619	IL-6	abstract[188]|abstract[191]	new[188]|giv[191]	_	_
21-54	3620-3622	in	abstract[188]|abstract[191]	new[188]|giv[191]	_	_
21-55	3623-3629	plasma	abstract[188]|abstract[191]|place	new[188]|giv[191]|new	_	_
21-56	3630-3631	.	_	_	_	_

#Text=The systemic inflammatory environment created by the arthritis induction leads to decreased metabolic activity and proliferation of CIA-derived MSC , and increased differentiation capacity determined by the expression of osteogenic ( runt-related transcription factor 2 ( RUNX2 ) and alkaline phosphatase ( ALP ) ) , and chondrogenic ( aggrecan ( ACAN ) ) markers in basal conditions .
22-1	3632-3635	The	abstract[193]	new[193]	_	_
22-2	3636-3644	systemic	abstract[193]	new[193]	_	_
22-3	3645-3657	inflammatory	abstract[193]	new[193]	_	_
22-4	3658-3669	environment	abstract[193]	new[193]	_	_
22-5	3670-3677	created	_	_	_	_
22-6	3678-3680	by	_	_	_	_
22-7	3681-3684	the	abstract[195]	giv[195]	_	_
22-8	3685-3694	arthritis	abstract|abstract[195]	giv|giv[195]	_	_
22-9	3695-3704	induction	abstract[195]	giv[195]	_	_
22-10	3705-3710	leads	_	_	_	_
22-11	3711-3713	to	_	_	_	_
22-12	3714-3723	decreased	abstract[197]	giv[197]	_	_
22-13	3724-3733	metabolic	person|abstract[197]	new|giv[197]	_	_
22-14	3734-3742	activity	abstract[197]	giv[197]	_	_
22-15	3743-3746	and	_	_	_	_
22-16	3747-3760	proliferation	event[198]	new[198]	_	_
22-17	3761-3763	of	event[198]	new[198]	_	_
22-18	3764-3775	CIA-derived	event[198]|abstract|object[200]	new[198]|new|giv[200]	_	_
22-19	3776-3779	MSC	event[198]|object[200]	new[198]|giv[200]	_	_
22-20	3780-3781	,	_	_	_	_
22-21	3782-3785	and	_	_	_	_
22-22	3786-3795	increased	_	_	_	_
22-23	3796-3811	differentiation	abstract|abstract[202]	new|new[202]	_	_
22-24	3812-3820	capacity	abstract[202]	new[202]	_	_
22-25	3821-3831	determined	_	_	_	_
22-26	3832-3834	by	_	_	_	_
22-27	3835-3838	the	abstract[203]	giv[203]	_	_
22-28	3839-3849	expression	abstract[203]	giv[203]	_	_
22-29	3850-3852	of	abstract[203]	giv[203]	_	_
22-30	3853-3863	osteogenic	abstract[203]|abstract	giv[203]|new	_	_
22-31	3864-3865	(	abstract[203]	giv[203]	_	_
22-32	3866-3878	runt-related	abstract[203]|abstract[206]	giv[203]|new[206]	appos	22-37[0_206]
22-33	3879-3892	transcription	abstract[203]|abstract|abstract[206]	giv[203]|new|new[206]	_	_
22-34	3893-3899	factor	abstract[203]|abstract[206]	giv[203]|new[206]	_	_
22-35	3900-3901	2	abstract[203]|abstract[206]	giv[203]|new[206]	_	_
22-36	3902-3903	(	abstract[203]	giv[203]	_	_
22-37	3904-3909	RUNX2	abstract[203]|abstract	giv[203]|giv	_	_
22-38	3910-3911	)	abstract[203]	giv[203]	_	_
22-39	3912-3915	and	abstract[203]	giv[203]	_	_
22-40	3916-3924	alkaline	abstract[203]|abstract[208]	giv[203]|new[208]	appos	22-43[0_208]
22-41	3925-3936	phosphatase	abstract[203]|abstract[208]	giv[203]|new[208]	_	_
22-42	3937-3938	(	_	_	_	_
22-43	3939-3942	ALP	abstract	giv	_	_
22-44	3943-3944	)	_	_	_	_
22-45	3945-3946	)	_	_	_	_
22-46	3947-3948	,	_	_	_	_
22-47	3949-3952	and	_	_	_	_
22-48	3953-3965	chondrogenic	abstract[210]	new[210]	_	_
22-49	3966-3967	(	abstract[210]	new[210]	_	_
22-50	3968-3976	aggrecan	abstract[210]|person	new[210]|new	_	_
22-51	3977-3978	(	abstract[210]	new[210]	_	_
22-52	3979-3983	ACAN	abstract[210]|abstract	new[210]|new	_	_
22-53	3984-3985	)	abstract[210]	new[210]	_	_
22-54	3986-3987	)	abstract[210]	new[210]	_	_
22-55	3988-3995	markers	abstract[210]|abstract[213]	new[210]|new[213]	_	_
22-56	3996-3998	in	abstract[210]|abstract[213]	new[210]|new[213]	_	_
22-57	3999-4004	basal	abstract[210]|abstract[213]|abstract[214]	new[210]|new[213]|giv[214]	_	_
22-58	4005-4015	conditions	abstract[210]|abstract[213]|abstract[214]	new[210]|new[213]|giv[214]	_	_
22-59	4016-4017	.	_	_	_	_
